Jazz Pharmaceuticals PLC (JAZZ) Position Cut by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH lessened its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 53.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,316 shares of the specialty pharmaceutical company’s stock after selling 2,659 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Jazz Pharmaceuticals PLC were worth $360,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. US Bancorp DE boosted its position in shares of Jazz Pharmaceuticals PLC by 94.4% during the 2nd quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 368 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in shares of Jazz Pharmaceuticals PLC by 43.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after purchasing an additional 295 shares in the last quarter. World Asset Management Inc bought a new position in shares of Jazz Pharmaceuticals PLC during the 1st quarter valued at about $205,000. Gargoyle Investment Advisor L.L.C. bought a new position in shares of Jazz Pharmaceuticals PLC during the 2nd quarter valued at about $206,000. Finally, Janney Montgomery Scott LLC bought a new position in shares of Jazz Pharmaceuticals PLC during the 2nd quarter valued at about $211,000. Hedge funds and other institutional investors own 88.24% of the company’s stock.

Several equities analysts have recently weighed in on JAZZ shares. Wells Fargo & Company restated an “outperform” rating and set a $177.00 price objective (down previously from $178.00) on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. BidaskClub lowered shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd. Piper Jaffray Companies restated an “overweight” rating and set a $182.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, June 7th. Vetr upgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 price objective for the company in a research report on Tuesday, June 6th. Finally, Cowen and Company restated an “outperform” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, June 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and nineteen have issued a buy rating to the company’s stock. Jazz Pharmaceuticals PLC currently has an average rating of “Buy” and an average target price of $180.96.

In related news, EVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $154.97, for a total value of $30,994.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total value of $153,520.00. The disclosure for this sale can be found here. Insiders sold a total of 8,717 shares of company stock valued at $1,346,617 over the last quarter. 4.30% of the stock is owned by insiders.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 152.65 on Tuesday. The stock has a market capitalization of $9.17 billion, a price-to-earnings ratio of 23.51 and a beta of 1.13. The stock has a 50 day moving average of $148.89 and a 200-day moving average of $150.40. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business had revenue of $394.39 million during the quarter, compared to analyst estimates of $410.83 million. During the same quarter in the prior year, the firm posted $2.67 earnings per share. Jazz Pharmaceuticals PLC’s revenue for the quarter was up 3.5% compared to the same quarter last year. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post $10.89 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Jazz Pharmaceuticals PLC (JAZZ) Position Cut by Fort Washington Investment Advisors Inc. OH” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/19/jazz-pharmaceuticals-plc-jazz-position-cut-by-fort-washington-investment-advisors-inc-oh.html.

Jazz Pharmaceuticals PLC Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply